{"id":"https://openalex.org/W2066735345","doi":"https://doi.org/10.1097/00126334-200404010-00007","title":"A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1???Infected Patients","display_name":"A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1???Infected Patients","alternate_titles":[],"publication_year":2004,"publication_date":"2004-03-08","ids":{"openalex":"https://openalex.org/W2066735345","doi":"https://doi.org/10.1097/00126334-200404010-00007","mag":"2066735345","pmid":"https://pubmed.ncbi.nlm.nih.gov/15097154"},"language":"en","primary_location":{"id":"doi:10.1097/00126334-200404010-00007","doi":"https://doi.org/10.1097/00126334-200404010-00007","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00126334-200404010-00007","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2066735345"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033836920","display_name":"Scott H. McCallister","orcid":"https://orcid.org/0000-0002-2536-3188","observed_orcids":["https://orcid.org/0000-0002-2536-3188"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Scott McCallister","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA. smccalli@rdg.boehringer-ingelheim.com","Boehringer Ingelheim Pharmaceuticals Inc. , Ridgefield, CT, 06877, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA. smccalli@rdg.boehringer-ingelheim.com","institution_ids":["https://openalex.org/I4210160255"]},{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals Inc. , Ridgefield, CT, 06877, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089961811","display_name":"Hern\u00e1n Valdez","orcid":"https://orcid.org/0000-0001-8058-1922","observed_orcids":["https://orcid.org/0000-0001-8058-1922"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Hernan Valdez","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, and \u2020Pharmacia, Kalamazoo, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, and \u2020Pharmacia, Kalamazoo, MI","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074618255","display_name":"Kevin Curry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Kevin Curry","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, and \u2020Pharmacia, Kalamazoo, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, and \u2020Pharmacia, Kalamazoo, MI","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045416293","display_name":"Thomas R. MacGregor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Thomas MacGregor","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, and \u2020Pharmacia, Kalamazoo, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, and \u2020Pharmacia, Kalamazoo, MI","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005253197","display_name":"Marie T. Borin","orcid":"https://orcid.org/0000-0002-1561-4051","observed_orcids":["https://orcid.org/0000-0002-1561-4051","https://orcid.org/0000-0002-4948-7943"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marie Borin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050486969","display_name":"William W. Freimuth","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"William Freimuth","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032188253","display_name":"Yenyung Wang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yenyung Wang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5111932686","display_name":"Douglas L. Mayers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Douglas L. Mayers","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, and \u2020Pharmacia, Kalamazoo, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, and \u2020Pharmacia, Kalamazoo, MI","institution_ids":["https://openalex.org/I4210160255"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5033836920","https://openalex.org/A5045416293","https://openalex.org/A5074618255","https://openalex.org/A5089961811","https://openalex.org/A5111932686"],"corresponding_institution_ids":["https://openalex.org/I4210160255"],"apc_list":null,"apc_paid":null,"fwci":6.7602,"has_fulltext":false,"cited_by_count":52,"citation_normalized_percentile":{"value":0.97256978,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"35","issue":"4","first_page":"376","last_page":"382"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tipranavir","display_name":"tipranavir","score":1.0},{"id":"https://openalex.org/keywords/hiv-1-infection","display_name":"HIV-1 infection","score":0.9490000009536743},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.9200000166893005},{"id":"https://openalex.org/keywords/ritonavir","display_name":"ritonavir","score":0.8389999866485596},{"id":"https://openalex.org/keywords/self-emulsifying-drug-delivery-systems","display_name":"self-emulsifying drug delivery systems","score":0.9259999990463257},{"id":"https://openalex.org/keywords/viral-load-reduction","display_name":"viral load reduction","score":0.7940000295639038},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8809999823570251},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.699999988079071},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5270000100135803},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.8320000171661377}],"concepts":[{"id":"https://openalex.org/C2779298103","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Ritonavir","level":5,"score":0.810492992401123},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8056690692901611},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6602466106414795},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.649702787399292},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6300644874572754},{"id":"https://openalex.org/C2781143361","wikidata":"https://www.wikidata.org/wiki/Q55761529","display_name":"Protease inhibitor (pharmacology)","level":5,"score":0.5940451622009277},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.5644166469573975},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5235354900360107},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4567798376083374},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.41243308782577515},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.27795296907424927},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.2187262773513794},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.10755100846290588}],"mesh":[{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D011753","descriptor_name":"Pyrones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011753","descriptor_name":"Pyrones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011753","descriptor_name":"Pyrones","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D017320","descriptor_name":"HIV Protease Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D017320","descriptor_name":"HIV Protease Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D017320","descriptor_name":"HIV Protease Inhibitors","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D018791","descriptor_name":"CD4 Lymphocyte Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00126334-200404010-00007","doi":"https://doi.org/10.1097/00126334-200404010-00007","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00126334-200404010-00007","pdf_url":null,"source":{"id":"https://openalex.org/S157460402","display_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","issn_l":"1525-4135","issn":["1525-4135","1944-7884"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","raw_type":"journal-article"},{"id":"pmid:15097154","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15097154","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of acquired immune deficiency syndromes (1999)","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":11,"referenced_works":["https://openalex.org/W1651794786","https://openalex.org/W1981719094","https://openalex.org/W1988525115","https://openalex.org/W2005104005","https://openalex.org/W2007788465","https://openalex.org/W2011630381","https://openalex.org/W2021626059","https://openalex.org/W2067274937","https://openalex.org/W2078078371","https://openalex.org/W2106571163","https://openalex.org/W2171909957"],"related_works":["https://openalex.org/W2127537255","https://openalex.org/W2010933020","https://openalex.org/W1985285378","https://openalex.org/W2171793178","https://openalex.org/W2009325269","https://openalex.org/W2015361827","https://openalex.org/W2025685004","https://openalex.org/W2133338060","https://openalex.org/W2228399041","https://openalex.org/W2083580679"],"abstract_inverted_index":{"Tipranavir":[0],"(TPV),":[1],"a":[2,18,31],"novel":[3],"nonpeptidic":[4],"protease":[5],"inhibitor":[6],"(NPPI),":[7],"was":[8,115,140],"administered":[9],"to":[10,24,51,169,175],"treatment-naive":[11],"HIV-1-infected":[12],"patients":[13,46,61,76],"over":[14],"14":[15,107,183],"days":[16,184],"in":[17,38,112,118,125,133,146],"randomized,":[19],"multicenter,":[20],"open-label,":[21],"parallel-group":[22],"trial":[23],"evaluate":[25],"the":[26,44,109,119,126,134,147],"efficacy":[27],"and":[28,74,94,102,130,144,150,179],"tolerability":[29],"of":[30,185],"self-emulsifying":[32],"drug":[33],"delivery":[34],"system":[35],"(SEDDS)":[36],"formulation,":[37],"combination":[39],"with":[40,155,167],"ritonavir":[41],"(RTV).":[42],"Of":[43],"31":[45],"enrolled,":[47],"10":[48,60],"were":[49,98,160],"randomized":[50],"receive":[52],"TPV":[53,63,78,120,138,156],"1200":[54,79,121,157],"mg":[55,65,69,80,84],"twice":[56,70,85],"daily":[57,71,86],"(TPV":[58],"1200),":[59],"received":[62,77],"300":[64],"+":[66,81],"RTV":[67,82],"200":[68,83],"(TPV/r":[72,87],"300/200),":[73],"11":[75],"1200/200).":[88],"The":[89],"median":[90,110],"baseline":[91],"viral":[92,113],"load":[93,114],"CD4":[95],"cell":[96],"count":[97],"4.96":[99],"log10":[100,117,124,132],"copies/mL":[101],"244":[103],"cells/mm,":[104],"respectively.":[105],"After":[106],"days,":[108],"decrease":[111],"-0.77":[116],"group,":[122,129],"-1.43":[123],"TPV/r":[127,135,148,173],"300/200":[128,149],"-1.64":[131],"1200/200":[136,151],"group.":[137],"exposure":[139],"increased":[141],"by":[142],"24-":[143],"70-fold":[145],"groups,":[152],"respectively,":[153],"compared":[154],"alone.":[158],"There":[159],"no":[161],"significant":[162],"differences":[163],"across":[164],"treatment":[165],"arms":[166],"regard":[168],"drug-related":[170],"adverse":[171],"events.":[172],"appeared":[174],"be":[176],"safe,":[177],"effective,":[178],"well":[180],"tolerated":[181],"during":[182],"treatment.":[186]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2066735345","counts_by_year":[{"year":2016,"cited_by_count":2},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
